ArticleBMC psychiatry2026
Unexpected resolution of clozapine-induced obsessive-compulsive symptoms with cariprazine augmentation: a case report.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe management of obsessive–compulsive symptoms (OCS) in patients with schizophrenia is challenging, as many antipsychotics can induce OCS. Increasing evidence supports the use of partial agonists in managing these cases. This case report describes a patient with treatment-resistant schizophrenia and clozapine-induced obsessive–compulsive symptoms who underwent multiple antipsychotic regimens without significant improvement. THE PATIENT’S MAIN CONCERNS AND IMPORTANT CLINICAL
findingsThe patient's symptoms progressed gradually, and their condition was managed entirely on an outpatient basis. Despite multiple adjustments to antipsychotic medications (risperidone, then haloperidol, then aripiprazole), the patient showed only a partial response to treatment, leading to their classification as treatment-resistant. THE PRIMARY DIAGNOSES, INTERVENTIONS, AND OUTCOMES: Due to the lack of adequate response, the medical team decided to prescribe clozapine. However, at a dose of 350 mg, clozapine triggered compulsive checking and washing behaviors. Consequently, the team initiated treatment with a third-generation antipsychotic, cariprazine, at a dose of 6 mg, combined with sertraline at 100 mg while gradually reducing clozapine. Unexpectedly, there was a significant improvement in both psychotic symptoms and OCS.
conclusionThe combination of cariprazine, as a D3 partial agonist, with clozapine may be an effective approach for managing challenging cases of treatment-resistant schizophrenia associated with de novo OCS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.